Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma

Published:2022-11-08 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Wang Jizhuang,Hu Fangqiong,Yu Pei,Wang Jun,Liu Zhuochao,Bao Qiyuan,Zhang Weibin,Wen Junxiang

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04458-4.pdf

Reference41 articles.

1. Alizadeh D, Trad M, Nt H, Cb L, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N (2014) Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Can Res 74(1):104–118. https://doi.org/10.1158/0008-5472.can-13-1545

2. Bielack S, Carrle D, Casali PG, Working GEG (2009) Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:137–139. https://doi.org/10.1093/annonc/mdp154

3. Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, Mcgarry SV, Mcgrath B, Morris CD, O’donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Von Mehren M, Bergman MA, Sundar H (2013) Bone cancer clinical practice guidelines in oncology. J Natl Comphr Cancer Netw 11(6):688–723

4. Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012

5. Chen Y, Ma DG, Molyneux S, Mckee T, Waterhouse P, Jm P, Khokha R (2015) RANKL blockade prevents and treats aggressive osteosarcomas. Sci Transl Med 7(317):317ra197. https://doi.org/10.1126/scitranslmed.aad0295

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity;Advanced Materials;2024-08-23

2. Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress;Cell Death Discovery;2024-08-08

3. Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges;Cancers;2024-06-12

4. Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies;Frontiers in Cell and Developmental Biology;2024-06-10

5. Single-cell transcriptional profiling in osteosarcoma and the effect of neoadjuvant chemotherapy on the tumor microenvironment;Journal of Bone Oncology;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3